Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of -41.30% is 936% below its 3-year average of 4.94%, near the high end of its 3-year range (-614.38%–13.41%).
65.53% above its 12-month average of -119.82%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): -9.80%.
GROSS MARGIN
-41.30%
GROSS MARGIN AVG TTM
-119.82%
GROSS MARGIN AVG 3Y
4.94%
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+65.53%
CURRENT VS 3Y AVG
-936.45%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-200.23%
vs the sector median at left
Market Cap
$8.14M
Gross Margin
N/A
TTM Avg
-2933.43%
3Y Avg
-1696.98%
5Y Avg
-1166.77%
Market Cap
$7.92M
Gross Margin
100.00%
TTM Avg
97.34%
3Y Avg
98.67%
5Y Avg
99.12%
Market Cap
$7.87M
Gross Margin
0.00%
TTM Avg
-261.58%
3Y Avg
-106.09%
5Y Avg
-70.73%
Market Cap
$8.33M
Gross Margin
18.37%
TTM Avg
19.16%
3Y Avg
20.84%
5Y Avg
23.00%
Market Cap
$7.75M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$7.67M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$7.64M
Gross Margin
54.43%
TTM Avg
58.30%
3Y Avg
57.46%
5Y Avg
45.97%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DataMEDS AI, Inc. (MEDS) | $8.05M | -41.30% | -119.82% | 4.94% | N/A |
| GT Biopharma, Inc. (GTBP)vs › | $8.04M | 0.00% | 0.00% | 0.00% | 0.00% |
| HeartSciences Inc. (HSCS)vs › | $8.14M | N/A | -2933.43% | -1696.98% | -1166.77% |
| Traws Pharma, Inc. (TRAW)vs › | $7.92M | 100.00% | 97.34% | 98.67% | 99.12% |
| Aprea Therapeutics, Inc. (APRE)vs › | $7.87M | 0.00% | -261.58% | -106.09% | -70.73% |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.33M | 18.37% | 19.16% | 20.84% | 23.00% |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.75M | 0.00% | 0.00% | 0.00% | 0.00% |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.67M | 0.00% | 0.00% | 0.00% | 0.00% |
| Mangoceuticals, Inc. (MGRX)vs › | $7.64M | 54.43% | 58.30% | 57.46% | 45.97% |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.46M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
-41.3%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | -9.80% |
| 2026-03-31 | 10.91% |
| 2025-12-31 | -614.38% |
| 2025-09-30 | 7.67% |
| 2025-06-30 | 6.49% |
| 2025-03-31 | 6.38% |
| 2024-12-31 | 4.85% |
| 2024-09-30 | 0.95% |
| 2024-06-30 | 13.41% |
| 2024-03-31 | 10.33% |
| 2023-12-31 | 8.07% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
